Stem Cell Therapy for Myocardial Infarction: A Mini-Review

  • Md Sadique Hussain School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.
  • Swati Tyagi Quantum School of Health Sciences, Department of Pharmacy, Quantum University, Roorkee, Uttarakhand 247662, India.
  • Himanshi Khatri School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.
  • Sandeep Singh School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

Abstract

Stem cells are undifferentiated cells that can proliferate, regenerate, develop into differentiated cells, and produce a variety of tissues. Embryonic stem cells, adult or somatic stem cells, and pluripotent stem cells are the three types of stem cells. Another classification of stem cells is totipotent, multipotent, and unipotent cells. Stem cell treatment has the possibility of treating degenerative disorders, cancer, and the restoration of damaged tissues, all of which now have no or restricted medicinal alternatives. Myocardial infarction is a potentially fatal condition caused by the permanent loss of cardiomyocytes and a deterioration in the heart's blood-pumping capacity. Throughout the last two decades, stem cell-based treatments for myocardial infarction therapy have been researched with encouraging results. Traditional therapy for myocardial infarction slows disease development but has little effect on healing. Because of their ability to initiate de novo cardiogenesis, embryonic stem cells are thought to be a potential candidate for cardiac regeneration.


 

Keywords: Myocardial Infarction; stem cell therapy; pluripotent stem cells; adult stem cells

Downloads

Download data is not yet available.

Author Biographies

Md Sadique Hussain, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

Swati Tyagi, Quantum School of Health Sciences, Department of Pharmacy, Quantum University, Roorkee, Uttarakhand 247662, India.

Quantum School of Health Sciences, Department of Pharmacy, Quantum University, Roorkee, Uttarakhand 247662, India.

Himanshi Khatri, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

Sandeep Singh, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India.

References

1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959.
2. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525. 4.
3. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Circulation. 2007; 116:2634–2653.
4. Kataria T, Hussain MS, Kaur G, Deb A. Emerging Nanoparticles in the Diagnosis of Atherosclerosis. International Journal of Pharmaceutical Science Review and Research. 2021; 70(2):46-57.
5. Lopez AD, Murray C. The global burden of disease, 1990 2020. Nat Med. 1998; 4:1241- 1243.
6. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009; 119(9):1211-1219.
7. Centers for Disease Control and Prevention. Underlying Cause of Death, 1999–2018. CDC WONDER Online Database. Atlanta, GA: Centers for Disease Control and Prevention; 2018.
8. Botta R, Gao E, Stassi G, et al. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J. 2004; 18(12):1392-1394.
9. Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res. 2016; 119(1):91-112.
10. Senyo SE, Steinhauser ML, Pizzimenti CL, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature. 2013; 493(7432):433-436.
11. Le TY, Thavapalachandran S, Kizana E, Chong JJ. New Developments in Cardiac Regeneration. Heart Lung Circ. 2017; 26(4):316-322.
12. Arjmand B, Abedi M, Arabi M, Alavi-Moghadam S, Rezaei-Tavirani M, Hadavandkhani M, Tayanloo-Beik A, Kordi R, Roudsari PP, Larijani B. Regenerative Medicine for the Treatment of Ischemic Heart Disease; Status and Future Perspectives. Frontiers in Cell and Developmental Biology. 2021:2171.
13. Klyachkin YM, Karapetyan AV, Ratajczak MZ, Abdel-Latif A. The role of bioactive lipids in stem cell mobilization and homing: novel therapeutics for myocardial ischemia. Biomed Res Int. 2014; 2014:653543.
14. van den Akker F, Deddens JC, Doevendans PA, Sluijter JP. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. BiochimBiophys Acta. 2013; 1830(2):2449-2458.
15. Kawaguchi N, Nakanishi T. Stem Cell Studies in Cardiovascular Biology and Medicine: A Possible Key Role of Macrophages. Biology. 2022; 11: 122.
16. Rasmussen JG, Frøbert O, Holst-Hansen C, Kastrup J, Baandrup U, Zachar V, et al. Comparison of Human Adipose-Derived Stem Cells and Bone Marrow-Derived Stem Cells in a Myocardial Infarction Model. Cell Transplantation. 2014; 23:195–206.
17. Bruun K, Schermer E, Sivendra A, Valaik E, Wise RB, Said R, et al. Therapeutic applications of adipose-derived stem cells in cardiovascular disease. American Journal of Stem Cells. 2018; 7(4): 94-103.
18. Squillaro T, Peluso G, Galderisi U. Clinical Trials with Mesenchymal Stem Cells: An Update. Cell Transplantation. 2016; 829-848.
19. Hotta Y. Ethical issues of the research on human embryonic stem cells. J Int Bioethique. 2008; 19(3):77-125.
20. Liang H, Matzkies M, Schunkert H, et al. Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell PhysiolBiochem. 2010; 25(4-5):459-466.
21. Almalki SG, Agrawal DK. Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation. 2016;92(1-2):41-51.
22. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):e00191.
23. Ardeshirylajimi A, Rafeie F, Zandi-Karimi A, et al. Fat harvesting site is an important determinant of proliferation and pluripotency of adipose-derived stem cells. Biologicals. 2016; 44(1):12-18.
24. Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007; 82(3):252-264.
25. Suzuki H, Romano-Spica V, Papas TS, Bhat NK. ETS1 suppresses tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 1995; 92(10):4442-4446.
26. Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013; 341(6146):651-654.
27. Mohammadi Amirabad L, Massumi M, Shamsara M, et al. Enhanced Cardiac Differentiation of Human Cardiovascular Disease Patient-Specific Induced Pluripotent Stem Cells by Applying Unidirectional Electrical Pulses Using Aligned Electroactive Nanofibrous Scaffolds. ACS Appl Mater Interfaces. 2017; 9(8):6849-6864.
28. Saheera S, Nair RR. Column-Free Method for Isolation and Culture of C-Kit Positive Stem Cells from Atrial Explants. Methods Mol Biol. 2019; 2045:181-186.
29. Rupp S, Bauer J, von Gerlach S, et al. Pressure overload leads to an increase of cardiac resident stem cells. Basic Res Cardiol. 2012; 107(2):252.
30. Vicinanza C, Aquila I, Scalise M, et al. Adult cardiac stem cells are multipotent and robustly myogenic: c-kit expression is necessary but not sufficient for their identification. Cell Death Differ. 2017; 24(12):2101-2116.
31. Langstraat M, Musters KJS, Manintveld O, Masetti M, Potena L. Coronary artery disease in heart transplantation: new concepts for an old disease. Transpl Int. 2018; 31(8):787-827.
32. de Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion. 2001; 41(2):190-195.
33. Assmus B, Schächinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002; 106(24):3009-3017.
34. Chen Y, Xu H, Liu J, Zhang C, Leutz A, Mo X. The c-Myb functions as a downstream target of PDGF-mediated survival signal in vascular smooth muscle cells. BiochemBiophys Res Commun. 2007; 360(2):433-436.
35. Afroze T, Sadi AM, Momen MA, Gu S, Heximer S, Husain M. c-Myb-dependent inositol 1,4,5-trisphosphate receptor type-1 expression in vascular smooth muscle cells. ArteriosclerThrombVasc Biol. 2007; 27(6):1305-1311.
36. Bian SY, Liu HB, Liu HW, Zhu QW. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018; 26(5):1538-1542.
37. Dhingra S, Li P, Huang XP, et al. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. Circulation. 2013; 128(11 Suppl 1):S69-S78
Statistics
88 Views | 49 Downloads
How to Cite
Hussain, M., Tyagi, S., Khatri, H., & Singh, S. (2022). Stem Cell Therapy for Myocardial Infarction: A Mini-Review. Asian Journal of Pharmaceutical Research and Development, 10(2), 122-124. https://doi.org/https://doi.org/10.22270/ajprd.v10i2.1155